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Abstract 
The object of this study  ware to modulated the effect of Tacrolimus and Sirolimus in Humeral immunity epically 
on titration of antibody and interlukin-2  in albino male rats. Fiftieth adult albino male  rats were housed and 
arbitrarily divided into five equal groups (ten rats/ group)and administered as follows for 90 days :control group 
received distilled water ,groups  T1 received sirolimus therapeutics dose 0.02mg/ kg B.W and T2:received 
sirolimus  two fold dose  0.04mg/ kg BW and T3: received tacrolimus  therapeutic dose 0.05mg/ kg BW and 
T4:received tacrolimus two fold dose 0.1mg/ mg B W.blood sample ware collect from each group in 30,60,90 days 
of experimental .Passive  hemagglutination  test used to assessment titrations of antibody, direct  Enzyme Linked 
Immune Sorbent Assay  used to assessment titrations of interlukin-2.The results at 30 days the titration of 
interleukin-2 ware decreased in all treated groups as a camper with control group and the decreasing depended on 
the dose and the time of exposure. The more significant in T2 and T4 in .30,60,90 days of experimental and the 
Tacrolimus showed more significant in reduction of interlukin-2 titrations  than Sirolimus while  the titration of 
antibody also show decreased in all treated groups T1,T2,T3,and T4 showed significant (p<0.05) in 30,60,90 days 
in comparison with the control one. Also the all treated group showed more decreased in 60,90 day and that more 
clear than in 30 day of experimental .The sirolimus more significant  on the titrations of antibody than tacrolimus. 
Keywords:Tacrolimus, Sirolimus, interlukin-2, Antibody. 
 
Introduction 
Tacrolimus (also FK-506 or fujimycin, trade names Prograf , Advagraf Protopic is an immunosuppressive drug 
that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so 
lower the risk of organ rejection it is a 23-membered macrolide lactone discovered in 1984 from the fermentation 
broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. It reduces interleukin-2 (IL-
2) production by T-cells.with (1). Tacrolimus is a calcineuron inhibitor. It is also used in a topical preparation in 
the treatment of atopic dermatitis (eczema) with a dose of 0.5,1,3 and even 5 mg(2).sever refractory uveitis after 
bone marrow transplants with dose 5mg its primary use in veterinary medicine is for the treatment of 
Keratoconjunctivitis Sicca in dogs. Tacrolimus can also be used to treat dermatologic problems such as Superficial 
Keratitis, Miliary Dermatitis and Atopic Dermatitis (Veterinary customer survey results ,2013). Sirolimus  known 
as rapamycin, is a macrolide (one of a group of drugs containing a macrolide ring) produced by the bacteria 
Streptomyces hygroscopicus. It has immunosuppressant functions in humans and is used to prevent rejection in 
organ as treatmant with a dose of 2mg and profelalses transplantation; it is especially useful in kidney transplants. 
It prevents activation of T cells and B cells by inhibiting their response tointerleukin-2 (IL-2)(3). (. Sirolimus is 
also used as a coronary stent coating. Sirolimus works, in part, by eliminating old and abnormal white blood cells 
(4). Sirolimus is effective in mice with autoimmunity and in children with a rare condition called autoimmune 
lymphoproliferative syndrome (ALPS) (5). 
 
Materials and methods 
Fifty albino male  rats, aged 12-16 weeks with weight ranged (250-300g), supplied from the animal house of  the 
College of veterinary medicine Baghdad university  were used for the administration of tacrolimus and 
sirolimus .They were housed and maintained in a conventional animal facility, with controlled conditions of 
temperature (20 ± 5ºC). The animals were fed on special formula feed pellets and given water add libitum, 
throughout the experiment, each group of rats were housed in a plastic cage containing hard-wood chip as bedding. 
The bedding was changed every three days to ensure a clean environment. The rats that ware subjected to study 
ware  divided in five equal groups each one    consist of 10 rats and treated orally through  gastric lavage with 
tacrolimus and serolimus for 90 days as fallowing group one(T1) Administered 0.02 mg/kg b.w Sirolimus as 
therapeutic dose.Group tow (T2) Administered 0.04 mg/kg b.w Sirolimus as two fold dose.Group three(T3) 
Administered 0.05mg/kg b.w Tacrolimus as therapeutic dose .Group four(T4) Administered 0.1 mg/kg b.w 
Tacrolimus as two fold dose.Group fivecontrol administered distilled water. The  blood sample ware collect at 
30,60,90,days of experimental in tube continuing anticoagulation. After the blood drown from heart puncture from 
anesthetized rats (intramuscular injections of ketamine (90mg/ kg B.W.)and xylazine  (40mg/ kg B.W.) and then 
separate the serum which storeg in (-20 C) the used to measured the passive hemagglutination test by (Alton et al., 
1975) and the interlukin-2 titration by the Elisa protocol  titration  of commercial komobiotic company.  
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Results 
The result of interlukin-2 titration 
There are significant p<0.05 in the IL-2 titration in all  treated   group incomparison with IL2- titration of control 
group especially the decrease was proration the dose and time of exposure in desendigly manner 30,60,90 days  
the prominent reduction in IL-2 titration observed in both  treated group T2 and T4 which were received double 
dose of  sirolimus and tacrolimus respectively .IL-2 especially  after 90 day of treatment  in comparison with there  
titration after 30 day of treatment (table1)       
Table 1. titration of interlukin-2( IL-2 (pg/ml))in serum of male rat exposed orally to tacrolimus&sirolimus 
with therapeutic &two fold dose for 30,60,90 day 
Groups  Day  LSD value 
30 60 90 
Control 
 
298.41 ± 2.09 
A            a  
295.36 ± 2.09 
A          a 
297.32 ± 3.87 
A             a 
8.674 NS 
T1 
 
127.22 ± 13.89 
B             a 
93.31 ± 1.78 
B            b 
24.38 ± 61.49 
B             c 
29.441 * 
T2 
 
53.24 ± 2.09 
CD            a 
33.99 ± 1.98 
D            b 
15.94 ± 0.72 
B             c 
5.290 * 
T3 
 
83.25 ± 8.06 
C              a 
45.49 ± 1.07 
C             b 
30.49 ± 4.61 
B              b 
18.034 * 
T4 
 
41.92 ± 2.25 
DE            a 
28.67 ± 1.25 
E            b 
17.02 ± 0.95 
B              c 
4.896 * 
LSD 
value 
22.019 * 4.987 * 42.073 * --- 
* (P<0.05). 
Different capital letters mean significant differences’ (P<0.05) between the group 
Different small latter mean significant diffrences (P<0.05) within the group 
periods. 
-T1= therapeutic dose of sirolimus (20µg/kg.B.W) dosing orally for 90 days. 
-T2=two fold dose of sirolimus (40 µg/kg.B.W) dosing orally for 90 days. 
-C=control group given distilled water orally. 
T3= therapeutic dose fo tacrolimus(50 µg/kg.B.W) dosing orally for 90 days 
T4= two fold dose of tacrolimus (100 µg/kg.B.W) dosing orally for 90 days-n=10 (number of animal). 
 
Result of passive hemaglutination test  
The All treated group T1,T2,T3,and T4 showed significant (p<0.05) in titration  decrease of antibodies  at 30,60,90 
days in comparison with the control one.Olso the All  treated group (T1,T2,T3,T4) showed 
significant( p<0.05)decrease in antibodies titer descending  with the period of exposure at 60and 90 day in 
comparison with there  value at 30 day of treatment( table 2)  
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Table 2Passive hemaglotination test (PHT) titration of antibody in serum of male rat that exposed to 
tacrolimus &sirolimus with therapeutic& tow fold dose after 30&60and 90 day 
Groups  Day  LSD 
value 30 60 90 
Control 
 
921.60 ± 298.54 
A               a 
563.20±125.41 
A        b 
422.40 ± 166.40 
A            bc 
172.45 
* 
T1 
 
358.40 ± 94.06 
B               a 
41.60 ± 9.60 
B          b 
18.40 ± 5.87 
B              b 
109.66 
* 
T2 
 
83.20 ± 19.20 
B                a 
27.20 ± 9.99 
B          b 
3.00 ± 1.41 
B              b 
31.85 * 
T3 
 
628.80 ± 182.34 
A               a 
41.60 ± 9.60 
B           b 
6.80 ± 2.49 
B              b 
128.64 
* 
T4 
 
236.80 ± 112.50 
    B                   a 
36.80 ± 11.7 
B           b 
2.80 ± 0.48 
B              b 
98.47 * 
LSD value 501.07 * 167.66 * 219.70 * --- 
* (P<0.05). 
Different capital letters mean significant (P<0.05) between the group 
Different small latter mean significant (P<0.05) within the group 
-T1= therapeutic dose of sirolimus (20µg/kg.B.W) dosing orally for 90 days. 
-T2=two fold dose of sirolimus (40 µg/kg.B.W) dosing orally for 90 days. 
T3= therapeutic dose fo tacrolimus(50 µg/kg.B.W) dosing orally for 90 days 
T4= two fold dose of tacrolimus (100 µg/kg.B.W) dosing orally for 90 days 
-C=control group given distilled water orally. 
 
Discussion 
Discussion of interlukin-2 
Interleukin is  a type of cytokine signaling molecule in the immune system. It is a protein that regulates the 
activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity. IL-2 is part of 
the body's natural response to microbial infection, and in discriminating between foreign ("non-self") and "self". 
IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes. Also   IL-2 has key 
roles in key functions of the immune system, tolerance and immunity, primarily via its direct effects on T cells. In 
the thymus, where T cells mature, it prevents autoimmune diseases by promoting the differentiation of certain 
immature T cells into regulatory T cells, which suppress other T cells that are otherwise primed to attack normal 
healthy cells in the body. IL-2 also promotes the differentiation of T cells into effector T cells and into memory T 
cells when the initial T cell is also stimulated by an antigen, thus helping the body fight off infections(6). Its 
expression and secretion is tightly regulated and functions as part of both transient positive and negative feedback 
loops in mounting immune responses and tamping them down. Through its role in the development of T cell 
immunologic memory, which depends upon the expansion of the number and function of antigen-selected T cell 
clones(7).dendritic cell( DCs) have previously been identified as a potential source of IL-2 cytokine. The  most 
effective stimuli to trigger IL-2 production in DCs by activating the calcineurin/NFAT signaling pathway.as for 
as (DCs), which have developed the capacity to respond to ligation of specific pathogen recognition receptors 
(PRRs) in order to trigger adaptive immune responses. many different responses induced by PRR ligation in DCs, 
the have  found that specific agonists can stimulate translocation of the transcription factor “nuclear factor of 
activated T-cells” (NFAT) to the DC nucleus . resulting in the activation and regulation of gene expression (8),(9). 
Interestingly, one of the gene products regulated by NFAT in DCs is the interleukin (IL)-2 (8). 
Tacrolimus is a calcenurin inhibitor leading to de-phosphorylated   of nuclear factor activated  T 
cell(NFAT) while the sirolimus block mammillae target of rapamycin leading to inhabit activation and 
proliferation of T cell,B cell and antigen presenting cell (APC) as for as Rapamycin inhibits IL-2-driven 
proliferation by down regulating the expression of genes required for key processes required for cell cycle 
progression(10).so it effect direct and indirect but the tacrolimus effective directly on NFAT  by inhibition of 
calcenurin(8). this effectiveness clearly appearing  in the rats interlukin-2 level  after  30 day of treatment  as 
compere with sirolimus that show less effective in level of interlukin-2 .but after 60 of treatment in the same period 
of treatment  showed there were  inhabited of IL-2 level still in the same manner as after 30 day of treatment 
representing by the more potential in the group that treated by tacrolimus as a compared with the group treated 
with sirolimus.After 90 day of exposure also we observed the sever inhibition of interlukin-2 level of all treated 
group ,but the story here is deferent since the treated sirolimus  group showed more potent inhibition after on the 
IL-2 level  incomparesion    to the group treated by tacrolimus ,we though this is may be have accumulative effect 
of sirolimus  after long standing treatment which not found in the calcenurin inhibitor(tacrolimus)  
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( 11). as for as there  are another way in case of sirolimus treatment there are more likely to event of the 
hepatotoxicity  which leading to increasing serum sirolimus concentration(12).  
 
Disccution of passive hemaaglutination test 
Passive hemaaglutenation test is a tools to detect humeral immunity that represent by antigen antibody reaction 
that show an a agglutinations mass.The titrations of agglutination reduced significantly in the groups that dosed 
sirolimus as a compere THE GROUPS group that dosed tacrolimus because the tacrolimus not directly effecting 
antibody production it inhibited T cell mitogen activated B cell immunoglobulin (IgG) productions (13). While 
the sirolimus directly affect the antibody production by inhibit the important cytokines to the 
proliferation,activation and remain survival of B cell which called PI3K which when activation leading to 
mobilization of calcium and B cell become   inhibited B cell activation and increase chance of apoptosis  and down 
stream so leading to decreasing IgG producing (14). 
Generally present study demonstrated that sirolimus   elicited lower value of  Abs titer as compare with 
tacrolimu.This may be associated with the potentiality of the sirolimus which consider more potent than tacrolimus 
for reduce    of CD4 Tcell and CD8 Tcell which depended on antigen exposure on APCs and density of peptide 
MHC –complex on APCs(15).more than tacrolimus 
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